Skip to content

Cardiovascular Metabolic Remodeling in Shock

Metabolic Remodeling Assessment During Severe Cardiovascular Dysfunction in Shock

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06285513
Acronym
METASHOCK
Enrollment
50
Registered
2024-02-29
Start date
2024-09-30
Completion date
2026-02-28
Last updated
2024-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shock

Keywords

Metabolic remodelling, Shock states, Cardiovascular dysfunction, Metabolomics

Brief summary

The aim of the study is to increase our knowledge of energy dysfunction in the cardiovascular dysfunction observed during shock states by analysing the omics molecules involved.

Detailed description

To do this, the investigators chose to carry out an in-depth study of the different metabolic pathways, using metabolomic analysis of plasma, targeting the cardiovascular metabolism of patients admitted to intensive care for septic and non-septic shocks.

Interventions

DIAGNOSTIC_TESTCardiac ultrasound

Cardiac ultrasound : determination of impairment of cardiac function by echocardiographic analysis (at V1, V3 and V4), Glycocheck : automatic analysis of sublingual microcirculation, Indirect calorimetry : determining the increase in energy expenditure in patients with septic shock

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patient aged between 18 and 75. * Patient admitted to intensive care for shock treated with a vasoactive or inotropic amine (adrenaline, dobutamine or noradrenaline).Patient undergoing invasive mechanical ventilation for less than 24 hours (or admitted to intensive care for less than 24 hours if the patient arrived intubated) and for a foreseeable duration of ventilation of at least 48 hours. * Patient, or relative if the patient is not competent, who has read and understood the information letter and does not object to participation in the research, or emergency procedure in the absence of a relative. * Urine or blood pregnancy test if a sample is taken as part of routine negative care (if woman of childbearing age).

Exclusion criteria

* Moribund patient (death expected within \< 24 hours) and/or decision to limit or stop treatment on admission to intensive care. * Pregnant, parturient or breast-feeding woman. * Patient not suitable for enteral calorie intake. Patient with a history of: advanced chronic renal failure ; advanced chronic liver failure. * Incapacitated patient of full age (under guardianship, curatorship) or deprived of liberty by court order. * Patient already taking part in an interventional study.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of the prognostic capacity of the initial metabolomic profile of patients in shockDay 3Correlation between plasma concentrations of metabolites at inclusion and delta of SOFA score (SOFA Day 1 - SOFA Day 3) with adjustment for SOFA at Day 1

Countries

France

Contacts

Primary ContactGrégoire JOLLY, MD
Gregoire.Jolly@chu-rouen.fr02 32 88 24 50
Backup ContactZoe DEMAILLY, MD
Zoe.Demailly@chu-rouen.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026